Rational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

ARYA Atherosclerosis is a distinguished open-access journal published by Isfahan University of Medical Sciences and the Isfahan Cardiovascular Research Center, with an ISSN of 1735-3955 and an E-ISSN of 2251-6638. Founded in 2005, this journal seeks to advance the field of cardiology and cardiovascular medicine by providing a platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings related to atherosclerosis and its implications for cardiovascular health. Although currently ranked in Q4 of its category in 2023, ARYA Atherosclerosis plays a vital role in the academic community by promoting open access to vital research, fostering collaboration, and encouraging the sharing of knowledge. The journal's commitment to transparency and accessibility makes it an essential resource for those looking to stay informed about the latest developments in cardiovascular research. Based in Iran, it is positioned within an emerging research landscape that is increasingly contributing to global health discussions.

Journal of Clinical Hypertension, published by WILEY, is a leading open-access journal focused on advancing the understanding and treatment of hypertension and related cardiovascular conditions. With an ISSN of 1524-6175 and an E-ISSN of 1751-7176, the journal provides a vital platform for researchers, healthcare professionals, and students alike to disseminate high-quality, peer-reviewed research. Since transitioning to open access in 2021, it has increased its reach and accessibility, ensuring critical information is available to a broader audience. The journal holds an impressive position in the Scopus ranks, nestled within the Q2 quartile across key disciplines including Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, and Internal Medicine, indicating a strong impact on the scientific community. With articles converging from 2001 to 2024, it not only highlights contemporary developments but also contributes to the ongoing dialogue in the field. Researchers are encouraged to submit their findings on hypertension, treatment methodologies, and epidemiology to further enhance the collective knowledge in this crucial area of health.

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

JOURNAL OF HYPERTENSION, published by Lippincott Williams & Wilkins, stands at the forefront of cardiovascular research, serving as a premier platform for the dissemination of knowledge in hypertension and related cardiovascular conditions. With an impressive impact factor, this esteemed journal is recognized in Q1 quartile across multiple categories, including Cardiology, Internal Medicine, and Physiology as of 2023, firmly establishing its significance within the academic community. The journal has been a reliable source of cutting-edge research since its inception in 1983, with continued publication through 2024. Researchers can expect a rigorous peer-review process and a diverse array of articles that include original research, reviews, and clinical studies aimed at enhancing the understanding and management of hypertension. Although it is not an open-access journal, the JOURNAL OF HYPERTENSION remains invaluable to clinicians, researchers, and students dedicated to advancing the field of cardiovascular health.

BLOOD PRESSURE MONITORING is a distinguished academic journal published by Lippincott Williams & Wilkins, dedicated to advancing the study of blood pressure measurement and management across various medical disciplines. With an ISSN of 1359-5237 and an E-ISSN of 1473-5725, this journal has consistently contributed to the field since its inception in 1996, continuing to provide invaluable insights through 2024. Notably, the journal ranks in the Q2 quartile for Advanced and Specialized Nursing and Assessment and Diagnosis, illustrating its influence in these areas, while also making significant contributions to Cardiology, Internal Medicine, and broader Medical research. Although it does not currently offer open access, BLOOD PRESSURE MONITORING remains essential reading for researchers, healthcare professionals, and students, eager to stay at the forefront of blood pressure research and its critical implications in clinical practice. The journal's commitment to quality and rigor makes it a vital resource for anyone involved in the continuously evolving fields of cardiovascular health and patient monitoring.

Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

Journal fur Hypertonie is a leading academic journal published by KRAUSE & PACHERNEGG GMBH, dedicated to the critical field of hypertension research. Since its inception in 1998, the journal has served as a vital platform for disseminating pioneering studies and advancements in the diagnosis, treatment, and management of hypertension. Although its Scopus coverage was discontinued in 2016, the journal continues to hold significance within the academic community, evidenced by its ranking of #98 out of 124 in Internal Medicine, placing it in the 21st percentile. This reflects its targeted impact and relevance in the evolving landscape of cardiovascular research. With no Open Access options, the journal remains a specialized resource indispensable for researchers, healthcare professionals, and students focused on enhancing their understanding and clinical practices related to hypertension. The journal's address is MOZARTGASSE 10, GABLITZ 3003, AUSTRIA.

Diabetes Epidemiology and Management, published by Elsevier, is an innovative open-access journal that has been addressing the critical issues surrounding diabetes since its inception in 2021. This journal integrates a comprehensive exploration of the epidemiology, prevention, and management of diabetes, making it a pivotal resource within the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine. With a digital presence represented by E-ISSN 2666-9706, it currently holds a commendable position in the academic landscape, categorized in the Q3 quartile for both Endocrinology and Internal Medicine as per the 2023 metrics. The journal aims to enhance understanding and promote research on diabetes, offering authors a platform to share their findings with a global audience. Researchers, professionals, and students alike can benefit from this essential resource, which is dedicated to advancing the knowledge base and improving clinical practices in diabetes management. With open access options since 2021, the journal ensures that vital research is widely accessible, driving innovation and collaboration in the fight against diabetes.